/
IRON
$73.58-$1.20 (-1.61%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.9B
38M shares
52-week range
$40.00 – $99.50
56% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$53.69
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $322.0K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$322.0K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — |
| R&D | $28.2M | $25.2M | $33.4M | $69.3M | $96.7M | $170.6M |
| Operating income | −$34.0M | −$30.9M | −$47.5M | −$91.1M | −$129.7M | −$236.0M |
| EBITDA | −$33.7M | −$33.8M | −$46.7M | −$76.2M | −$108.3M | −$207.9M |
| Net income | −$40.8M | −$36.0M | −$46.8M | −$76.4M | −$109.4M | −$212.2M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -27.02 | -44.88 | -45.05 | -3.42 | -3.96 | -6.01 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $3M | $-6.96 | $-7.67–$-6.01 | 9 |
| 2027 | $32M | $-7.37 | $-8.75–$-6.28 | 8 |
| 2028 | $137M | $-5.74 | $-7.82–$-3.65 | 10 |
| 2029 | $327M | $-2.96 | $-4.50–$-1.97 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.31
Price
$73.58
Implied downside
-97%
Peer comparison
Disc Medicine, Inc. Common Stock
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
www.discmedicine.com- Employees
- 155
- IPO / List date
- Feb 8, 2021
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds IRON.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 31,820 | $2.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IRON yet.
